Cardiologists vs Endocrinologists in Glycemic Control for Coronary Artery Disease Patients with Type 2 Diabetes: A Cross-Sectional Study
Qin Xia,Qianwen Peng,Hefeng Chen,Weixia Zhang
DOI: https://doi.org/10.2147/jmdh.s494004
2024-12-04
Journal of Multidisciplinary Healthcare
Abstract:Qin Xia, Qianwen Peng, Hefeng Chen, Weixia Zhang Department of Pharmacy, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China Correspondence: Weixia Zhang, Email Background: The comorbidity of coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) presents significant challenges in clinical management, particularly regarding glycemic control. The clinical management of CAD complicated by T2DM requires coordinated glycemic control, as poor management can exacerbate cardiovascular risks and increase morbidity and mortality. While endocrinologists traditionally manage diabetes, cardiologists are increasingly involved due to the cardiovascular risks associated with poor glycemic control. This study explores the current practices of glycemic management by cardiologists and endocrinologists in patients with CAD and T2DM, focusing on treatment intensification in a Chinese hospital setting. Methods: This cross-sectional study included 1,074 hospitalized patients with both CAD and T2DM, admitted to the Cardiology Department of Ruijin Hospital between January 2021 and December 2023. Data were retrospectively collected from electronic medical records, including demographic information, clinical characteristics, and treatment interventions. Patients were stratified by year, and differences in treatment strategies between cardiologists and endocrinologists were analyzed. Glycemic control was assessed using HbA1c levels, with treatment intensification defined by any adjustment in antidiabetic therapy and consideration for comprehensive cardiovascular risk factors. Results: Endocrinologists were significantly more likely to initiate treatment intensification, especially in cases of severe hyperglycemia (HbA1c ≥ 9.0%), while cardiologists' role in glycemic management was limited, with a preference for outpatient endocrinology referrals over in-hospital adjustments. Despite improvements in glycemic control, the percentage of patients achieving comprehensive cardiovascular risk management targets remained low. Conclusion: This study underscored the distinct yet complementary roles of cardiologists and endocrinologists in managing glycemic control among patients with CAD and T2DM, noting endocrinologists' more active involvement in treatment intensification. Future integrated care models should harness the unique expertise of both specialties to optimize patient outcomes, better address glycemic control needs, and enhance overall cardiovascular risk management in this high-risk patient population. Keywords: coronary artery disease, type 2 diabetes mellitus, glycemic control, cardiologists, endocrinologists, treatment intensification The global rise in chronic non-communicable diseases has been driven by improvements in socioeconomic conditions, shifts in dietary patterns, and the aging population. Among these diseases, coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM) are particularly prevalent and often coexist in clinical practice. In China, where rates of both CHD and T2DM are rising, 1,2 addressing this comorbidity has become a significant healthcare priority. The complex interaction between these conditions poses particular challenges in hospital settings, where specialized care is often needed. This comorbidity significantly increases the risk of cardiovascular events, as each condition exacerbates the other, creating a vicious cycle that complicates patient management. Effective glycemic control is essential in treating patients with both CHD and T2DM, as it directly influences both short- and long-term outcomes, including the risk of myocardial infarction, heart failure, and overall mortality. 3,4 Traditionally, the management of glycemic control in patients with diabetes has been the domain of endocrinologists, who focus on optimizing blood glucose levels to prevent complications. However, the growing recognition of the interconnectedness between diabetes and cardiovascular disease has led to an increased involvement of cardiologists in managing glycemia, especially considering that cardiovascular diseases are the leading cause of death among T2DM patients. 5 Cardiologists are increasingly called upon to incorporate glycemic control into the broader context of cardiovascular risk management, as managing glycemic levels in patients with CHD and T2DM is complicated by the need to balance glycemic targets with cardiovascular safety, as overly aggressive glycemic control can sometimes lead to adverse cardiovascular events. This complexity underscores the need for clear, collaborative guidelines, especially with recent advancements in glucose-lowering therapies that offer cardiovascular benefits, such as SGLT2 inhibitors and GLP-1 -Abstract Truncated-
health care sciences & services